| Dermatitis, Atopic
Eucrisa vs Nemluvio
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Eucrisa vs Nemluvio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNemluvio has a higher rate of injection site reactions vs Eucrisa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nemluvio but not Eucrisa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eucrisa
Nemluvio
At A Glance
Topical
Twice daily
PDE-4 inhibitor
SC injection
Every 4 weeks
IL-31 receptor antagonist
Indications
- Dermatitis, Atopic
- Prurigo nodularis
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic Apply a thin layer twice daily to affected areas; once clinical effect is achieved, consider reducing to once daily. For topical use only.
Prurigo nodularis (<90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks.
Prurigo nodularis (>=90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 60 mg SC every 4 weeks.
Dermatitis, Atopic Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks; after 16 weeks, patients who achieve clear or almost clear skin may receive 30 mg every 8 weeks.
Contraindications
- Known hypersensitivity to crisaborole or any component of the formulation
- Known hypersensitivity to nemolizumab-ilto or any excipient in NEMLUVIO
Adverse Reactions
Most common (>=1%) Application site pain
Postmarketing Allergic contact dermatitis
Most common (>=1%) Headache, dermatitis atopic, eczema, eczema nummular (prurigo nodularis trials); headache, arthralgia, urticaria, myalgia (atopic dermatitis trials).
Serious Type 1 hypersensitivity reactions (IgE-mediated), including facial angioedema.
Pharmacology
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor; PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels, though the specific mechanism by which it treats atopic dermatitis is not well defined.
Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 receptor alpha (IL-31 RA); IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eucrisa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (10/12) · Qty limit (9/12)
Nemluvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Eucrisa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (4/8) · Qty limit (5/8)
Nemluvio
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (4/8)
Humana
Eucrisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Nemluvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eucrisa.
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EucrisaView full Eucrisa profile
NemluvioView full Nemluvio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.